Please ensure Javascript is enabled for purposes of website accessibility

Why MannKind Corp. Stock Skyrocketed Today

By George Budwell – Nov 10, 2016 at 11:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sanofi gives the biotech some much-needed breathing room.

Image source: Getty Images.

What happened

Shares of the embattled biotech MannKind Corp. (MNKD 1.00%) rose by more than 35% in early morning trading today. This sizable move northward is the result of both a stellar third-quarter earnings report coupled with Sanofi (SNY 1.16%) taking significant steps to resolve its outstanding obligations under the former license and collaboration agreement for MannKind's inhaled insulin product, Afrezza. Specifically, Sanofi agreed to forgive the balance of its $71.56 million loan to MannKind. and purchase $10.2 million worth of insulin from the biotech in early December. As of 11:47 a.m. EST, shares were up 34%.

So what

Even though MannKind hauled in $161.8 million in net revenue in Q3 as part of its former collaboration with Sanofi, the biotech is still in a precarious financial position with a mere $35.5 million of cash and cash equivalents remaining on its balance sheet at the end of the third quarter. Put simply, Sanofi's decision to simply forgive $71.56 million is a huge win for the company at this critical point in time. 

Now what

The bad news is that Mannkind's relaunch of Afrezza is off to a disappointing start. After all, the company reported a paltry $573,000 in Q3 sales outside of its collaboration with Sanofi. That's particularly disconcerting in light of the biotech's quarterly expenses, which came in at a whopping $44.12 million. 

MannKind is either going to have to find another partner willing to fork over some hefty upfront milestone payments, or raise funds by further diluting shareholders in order to stay afloat over the next year. Unfortunately, the odds of another biopharma picking up the inhaled insulin mantle at this stage appear to be exceedingly slim based on Afrezza's undeniably weak commercial trajectory thus far. In other words, this monstrous rally will probably be short-lived, given the company's problematic balance sheet and poor growth prospects moving forward.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.